Isodiol International Inc.. Subsidiary, BSPG Laboratories LTD., Launches API Sales and Marketing Program at CPhI 2018

Isodiol International Inc..

Subsidiary, BSPG Laboratories LTD., Launches API Sales and Marketing Program in CPhI 2018

 Isodiol International Inc.. (CSE: ISOL) (OTCQB: ISOLF), is pleased to offer a reliable supply of GMP-compliant cannabidiol (CBD), extracted from industrial hemp to pharmaceutical companies and research groups for human and animal use at CPhI 2018 in Madrid, Spain.

BSPG Laboratories, a U.K.-based subsidiary of Isodiol, is a manufacturer of GMP-compliant pure, natural CBD comprising no THC and maintains industry standards while focusing on leading scientific and pharmaceutical methods. The facility has been recently registered with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).

BSPG Laboratories generates non-synthetic CBD as research and clinical studies and an API for pharmaceutical applications to benefit the scientific and health care community — on a level.  

Isodiol CEO, Marcos Agramont stated, “CPhI is a 28-year established pharmaceutical event bringing together over 45,000 industry professionalstwo . We are excited to be taking the lead of supplying CBD as an API to the industry. ”

Meet with BSPG Laboratories in CPhI, October 9 — 11, 2018, Hall 5 stall 3H27. For further information or to contact BSPG Laboratories, please see BSPGlabs.com.

Around Isodiol International Inc..

Isodiol International Inc.. Is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based customer products and solutions.

Isodiol has commercialized a pure isolated CBD, such as micro-encapsulations, and nano-technology for topical skin care products and quality consumable. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient to be used in Finished Pharmaceutical Products, as was declared on April 26, 2018.

Isodiol&rsquo growth strategy involves the development of over-the-counter and pharmaceutical drugs and continued international expansion into Europe, Asia, and Latin America.

Twitter: @Isodiolintlinc

Marcos Agramont, CEO & Director

Ir@isodiol.com
www.isodiol.com

Forward-Looking Information: This news release contains”forward-looking information” within the meaning of applicable securities laws pertaining to statements regarding the Company’s business, products and future the organization ’s business, its product offerings and strategies for sales and promotion. There can be no assurance that such expectations will prove to be correct, although the Company believes that the expectations reflected in the forward-looking information are reasonable. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the corporation’s products and plan will be different from those mentioned in this news release and the Company might not be able to carry out its business plans as anticipated. Except as required by law, the Company does not intend, to update forward-looking information or any forward-looking statements in this news release and disclaims any obligation. Even though the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that these expectations will prove to be correct and makes no reference based on earnings reported. The statements in this news release are made as of the date of this release.

The CSE hasn’t reviewed, approved or disapproved the content of this press release.

__________________________

1https://www.cphi.com/
2https://www.cphi.com/

Isodiol.Logo.jpg

Source: GlobeNewswire (October 5, 2018 – 8:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

Published at Fri, 05 Oct 2018 12:02:51 +0000

Posted in: News

Comments are closed.